Overview

This trial is active, not recruiting.

Condition neoplasms
Sponsor Centre Hospitalier Universitaire de la Réunion
Start date January 2015
End date January 2017
Trial size 18000 participants
Trial identifier NCT02900287, 2014/CHU/05

Summary

Cancer survival is important to determine prognostic of patients and evaluate care and prevention health strategies. Sucre is the first study to describe cancer survival in Reunion Island. Sucre aims at evaluating five year cancer prognostic in Reunion Island by cancer site and gender. Sucre is a retrospective cohort study of cancer diagnosed between 01/01/1998 and 31/12/2008.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Primary Outcomes

Measure
5 years related survival rate by cancer site and gender
time frame: 5 years

Secondary Outcomes

Measure
1, 3, 5 and 10 years related survival rate by cancer site and gender
time frame: 1, 3, 5 and 10 years
1, 3, 5 and 10 years standardised survival rate by cancer site and gender
time frame: 1, 3, 5 and 10 years
1, 3, 5 and 10 years related survival rate by age at diagnosis
time frame: 1, 3, 5 and 10 years

Eligibility Criteria

Male or female participants at least 15 years old.

Inclusion Criteria: - Patients domiciled in Reunion Island at diagnosis - Patients with at least 15 years of age at diagnosis - Patients with cancer diagnosis between 01/01/1998 and 31/12/2008 Exclusion Criteria: - Cutaneous malignant cancer expected melanoma

Additional Information

Official title Survie Des Personnes Atteintes de Cancer à la Réunion, 1998-2008 (SUCRE)
Description Data are extracted from Reunion Island Cancer Registry.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Centre Hospitalier Universitaire de la Réunion.